Survivin promoter-regulated oncolytic adenovirus with Hsp70 gene exerts effective antitumor efficacy in gastric cancer immunotherapy

Oncotarget

Volumn 5, Issue 1, 2014, Pages 150-160

  Wang, Weiguo ^a   Ji, Weidan ^b   Hu, Huanzhang ^c   Ma, Juming ^a   Li, Xiaoya ^b   Mei, Weiqun ^a   Xu, Yang ^b   Hu, Huizhen ^a   Yan, Yan ^b   Song, Qizhe ^a   Li, Zhigang ^d   Su, Changqing ^b  

^a The 117th Hospital of Chinese PLA   (China)

^b SECOND MILITARY MEDICAL UNIVERSITY   (China)

^c FUZHOU GENERAL HOSPITAL   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Gastric cancer; Gene therapy; Heat shock protein; Oncolytic adenovirus; Survivin gene

Indexed keywords

HEAT SHOCK PROTEIN 70; ONCOLYTIC ADENOVIRUS; SURVIVIN PROMOTER REGULATED ONCOLYTIC ADENOVIRUS; UNCLASSIFIED DRUG; BIRC5 PROTEIN, MOUSE; INHIBITOR OF APOPTOSIS PROTEIN; ONCOLYTIC VIRUS; REPRESSOR PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CELL VIABILITY; CONTROLLED STUDY; CYTOLYSIS; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SPECIFICITY; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH CANCER; TRANSGENE; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; DRUG SCREENING; GENETICS; HEK293 CELL LINE; IMMUNOTHERAPY; METABOLISM; NUDE MOUSE; PHYSIOLOGY; PROCEDURES; PROMOTER REGION; STOMACH NEOPLASMS; TUMOR CELL LINE; VIROLOGY;

ANIMALS; CELL LINE, TUMOR; HEK293 CELLS; HSP70 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOTHERAPY; INHIBITOR OF APOPTOSIS PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC; REPRESSOR PROTEINS; STOMACH NEOPLASMS; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84893864404     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.1430     Document Type: Article

References (32)

1. Huang S, Kamihira M. Development of hybrid viral vectors for gene therapy. Biotechnol Adv. 2013;31:208-23.
2. Kron MW, Kreppel F. Adenovirus vectors and subviral particles for protein and peptide delivery. Curr Gene Ther. 2012;12:362-73.
3. Vacchelli E, Eggermont A, Sautès-Fridman C, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial watch: Oncolytic viruses for cancer therapy. Oncoimmunology. 2013;2:e24612.
4. Meshii N, Takahashi G, Okunaga S, Hamada M, Iwai S, Takasu A, Ogawa Y, Yura Y. Enhancement of systemic tumor immunity for squamous cell carcinoma cells by anoncolytic herpes simplex virus. Cancer Gene Ther. 2013; doi: 10.1038/cgt.2013.45.
5. Li JM, Kao KC, Li LF, Yang TM, Wu CP, Horng YM, Jia WW, Yang CT. MicroRNA-145 regulates oncolytic herpes simplex virus-1 for selective killing of human non-small cell lung cancer cells. Virol J. 2013;10:241.
6. Xu C, Li H, Su C, Li Z Viral therapy for pancreatic cancer: tackle the bad guys with poison. Cancer Lett. 2013;333:1-8.
7. Xu C, Sun Y, Wang Y, Yan Y, Shi Z, Chen L, Lin H, Lü S, Zhu M, Su C, Li Z. CEA promoter-regulated oncolytic adenovirus-mediated Hsp70 expression in immune gene therapy for pancreatic cancer. Cancer Lett. 2012;319:154-63.
8. Ma J, He X, Wang W, Huang Y, Chen L, Cong W, Gu J, Hu H, Shi J, Li L, Su C. E2F promoter-regulated oncolytic adenovirus with p16 gene induces cell apoptosis and exerts antitumor effect on gastric cancer. Dig Dis Sci. 2009;54:1425-31.
9. Su C, Na M, Chen J, Wang X, Liu Y, Wang W, Zhang Q, Li L, Long J, Liu X, Wu M, Fan X, Qian Q. Gene-viral cancer therapy using dual-regulated oncolytic adenovirus with antiangiogenesis gene for increased efficacy. Mol Cancer Res. 2008;6:568-75.
10. Zhang Y, Fang L, Zhang Q, Zheng Q, Tong J, Fu X, Jiang X, Su C, Zheng J. An oncolytic adenovirus regulated by a radiation-inducible promoter selectively mediates hSulf-1 gene expression and mutually reinforces antitumor activity of I131-metuximab in hepatocellular carcinoma. Mol Oncol. 2013;7:346-58.
11. Liu C, Sun B, An N, Tan W, Cao L, Luo X, Yu Y, Feng F, Li B, Wu M, Su C, Jiang X. Inhibitory effect of Survivin promoter-regulated oncolytic adenovirus carrying P53 gene against gallbladder cancer. Mol Oncol. 2011;5:545-54.
12. Calderwood SK, Stevenson MA, Murshid A. Heat shock proteins, autoimmunity, and cancer treatment. Autoimmune Dis. 2012;2012:486069.
13. Chen T, Cao X. Stress for maintaining memory: HSP70 as a mobile messenger for innate and adaptive immunity. Eur J Immunol. 2010;40:1541-4.
14. Böttger E, Multhoff G, Kun JF, Esen M. Plasmodium falciparum-infected erythrocytes induce granzyme B by NK cells through expression of host-Hsp70. PLoS One. 2012;7:e33774.
15. Chen X, Tao Q, Yu H, Zhang L, Cao X. Tumor cell membrane-bound heat shock protein 70 elicits antitumor immunity. Immunol Lett. 2002;84:81-7.
16. Chen T, Guo J, Han C, Yang M, Cao X. Heat shock protein 70, released from heat-stressed tumor cells, initiates antitumor immunity by inducing tumor cell chemokine production and activating dendritic cells via TLR4 pathway. J Immunol. 2009;182:1449-59.
17. Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 2002;20:395-425.
18. Morse MA, Clay TM, Hobeika AC, Osada T, Khan S, Chui S, Niedzwiecki D, Panicali D, Schlom J, Lyerly HK. Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. Clin Cancer Res. 2005;11:3017-24.
19. Kim TW, Lee JH, He L, Boyd DA, Hung CF, Wu TC. DNA vaccines employing intracellular targeting strategies and a strategy to prolong dendritic cell life generate a higher number of CD8+ memory T cells and better long-term antitumor effects compared with a DNA prime-vaccinia boost regimen. Hum Gene Ther. 2005;16:26-34.
20. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R, Pelusio A, Le Boeuf F, Burns J, Evgin L, De Silva N, Cvancic S, Robertson T, Je JE, Lee YS, Parato K, Diallo JS, Fenster A, Daneshmand M, Bell JC, Kirn DH. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 2011; 477:99-102.
21. Galanis E. Cancer: Tumour-fighting virus homes in. Nature. 2011 ; 477:40-1.
22. Patel MR, Kratzke RA. Oncolytic virus therapy for cancer: the first wave of translational clinical trials. Transl Res. 2013;161:355-64.
23. Groner B, Weiss A. Targeting Survivin in Cancer: Novel Drug Development Approaches. BioDrugs. 2013; doi: 10.1007/s40259-013-0058-x.
24. Cao L, Li C, Shen S, Yan Y, Ji W, Wang J, Qian H, Jiang X, Li Z, Wu M, Zhang Y, Su C. OCT4 increases BIRC5 and CCND1 expression and promotes cancer progression in hepatocellular carcinoma. BMC Cancer. 2013;13:82.
25. Li C, Yan Y, Ji W, Bao L, Qian H, Chen L, Wu M, Chen H, Li Z, Su C. OCT4 positively regulates Survivin expression to promote cancer cell proliferation and leads to poor prognosis in esophageal squamous cell carcinoma. PLoS One. 2012;7:e49693.
26. Murphy ME. The HSP70 family and cancer. Carcinogenesis. 2013;34:1181-8.
27. Behnsawy HM, Miyake H, Kusuda Y, Fujisawa M. Small interfering RNA targeting heat shock protein 70 enhances chemosensitivity in human bladder cancer cells. Urol Oncol. 2013;31:843-8.
28. Schmitt E, Gehrmann M, Brunet M, Multhoff G, Garrido C. Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy. J Leukoc Biol. 2007;81:15-27.
29. Ogawa T, Ono S, Ichikawa T, Arimitsu S, Onoda K, Tokunaga K, Sugiu K, Tomizawa K, Matsui H, Date I. Protein transduction method for cerebrovascular disorders. Acta Med Okayama. 2009;63:1-7.
30. Wu HL, Duan ZT, Jiang ZD, Cao WJ, Wang ZB, Hu KW, Gao X, Wang SK, He BS, Zhang ZY, Xie HG. Increased endoplasmic reticulum stress response is involved in clopidogrel-induced apoptosis of gastric epithelial cells. PLoS One. 2013;8:e74381.
31. Pan Y, He B, Lirong Z, Nie Z, Chen L, Gu L, Hoffman AR, Wang S, Hu J. Gene therapy for cancer through adenovirus vector-mediated expression of the Ad5 early region gene 1A based on loss of IGF2 imprinting. Oncol Rep. 2013;30:1814-22.
32. Todorovic M, Mesiano G, Gammaitoni L, Leuci V, Giraudo Diego L, Cammarata C, Jordaney N, Carnevale-Schianca F, Gallo S, Fagioli F, Piacibello W, Elia AR, Pignochino Y, Dell'aglio C, Grignani G, Cignetti A, Aglietta M, Sangiolo D. Ex vivo allogeneic stimulation significantly improves expansion of cytokine-induced killer cells without increasing their alloreactivity across HLA barriers. J Immunother. 2012;35:579-86.